Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00000646|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : March 30, 2012
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Pentoxifylline||Phase 1|
Pentoxifylline decreases tumor necrosis factor (TNF), and therefore should decrease such TNF-intensified events as cachexia, enhanced HIV expression, and inhibition of zidovudine (AZT) activity.
Twenty-seven AIDS patients with elevated TNF and less than 300 CD4 cells are given pentoxifylline 3 times a day for 8 weeks. If no significant changes are seen in virologic, immunologic, or related measures, 27 additional patients are given a higher dose of pentoxifylline 3 times a day for eight weeks.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||54 participants|
|Official Title:||Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS|
|Actual Study Completion Date :||March 1993|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000646
|United States, Massachusetts|
|Beth Israel Deaconess - East Campus A0102 CRS|
|Boston, Massachusetts, United States, 02215|
|United States, Ohio|
|Cleveland, Ohio, United States|
|Study Chair:||Dezube B|
|Study Chair:||Crumpacker C|